Charles River Laboratories ROI - Return on Investment 2010-2024 | CRL

Charles River Laboratories return on investment for the quarter ending June 30, 2024 was 7.2.

  • Charles River Laboratories average return on investment for 2023 was 8.29, a 0.12% decline from 2022.
  • Charles River Laboratories average return on investment for 2022 was 8.28, a 4.28% increase from 2021.
  • Charles River Laboratories average return on investment for 2021 was 8.65, a 10.76% decline from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

Charles River Laboratories ROI - Return on Investment 2010-2024 | CRL

  • Charles River Laboratories average return on investment for 2023 was 8.29, a 0.12% decline from 2022.
  • Charles River Laboratories average return on investment for 2022 was 8.28, a 4.28% increase from 2021.
  • Charles River Laboratories average return on investment for 2021 was 8.65, a 10.76% decline from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$99.6B
Cencora (COR)$48.8B
DiDi Global (DIDIY)$24.4B
ICON (ICLR)$17.7B
Natera (NTRA)$16.1B
Viatris (VTRS)$15.7B
Avantor (AVTR)$15.6B
Revvity (RVTY)$15.1B
BioMerieux (BMXMF)$13.1B
Solventum (SOLV)$13B
CochLear (CHEOY)$12.8B
Medpace Holdings (MEDP)$11B
Sonic Healthcare (SKHHY)$8.8B
HealthEquity (HQY)$8.5B
Doximity (DOCS)$8.1B
Bausch + Lomb (BLCO)$7.1B
Life Times (LTH)$5.1B
Sotera Health (SHC)$4.5B
Organon (OGN)$4.2B
Surgery Partners (SGRY)$3.9B
BrightSpring Health Services (BTSG)$3.3B
PACS (PACS)$3B
Alignment Healthcare (ALHC)$2.6B
Concentras Parent (CON)$2.6B
Ardent Health Partners (ARDT)$2.5B
Premier (PINC)$2.3B
GeneDx Holdings (WGS)$2.1B
Ryman Healthcare (RYHTY)$2B
GoodRx Holdings (GDRX)$1.9B
Teladoc Health (TDOC)$1.6B